After a busy year of manufacturing buildouts in 2022, Eli Lilly is already back at it with a $450 million investment. Lilly is planning to expand its facility in the Research Triangle in North Carolina, adding 100 new jobs at the facility, mainly manufacturing personnel.
The expansion, announced on Tuesday, is slated to be completed in 2027 and will add additional capacity for “parenteral filling” as well as more space for the assembly of devices and packaging capacity. Construction will begin this year, but no exact date has been set.
The expansion will also support and increase demand for its incretin products that help treat diabetes, Lilly said in a press release. However, there are no details on the size of the expansion. Endpoints News reached out for further comment but did not receive a response by press time.
Click here to view original post